• James H Flory, Scott Keating, Dominique Guelce, and Alvin I Mushlin.
• Endocrinology Service, Department of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• Patient Prefer Adher. 2019 Jan 1; 13: 1433-1441.

BackgroundMetformin is the first-line treatment for type 2 diabetes mellitus. Observational studies show lower rates of use than would be expected from clinical guidelines.ObjectiveWe undertook a qualitative study of barriers to metformin use from the patient and provider perspective.DesignPatient focus group, patient individual interviews, provider interviews, and chart review. Purposive sampling of patients and providers in New York State.ParticipantsSeven one-on-one patient interviews, one focus group with 13 patients, 10 provider interviews, and manual review of 1259 charts.ApproachGrounded theory.ResultsBoth providers and patients cited potential health benefits as strong reasons to take metformin and describe it as the first-line drug for diabetes. Patients and providers both cited gastrointestinal side effects as the primary barrier to metformin use. Patients described adapting to these side effects and taking metformin at a time that minimizes them. In contrast, providers emphasized dose titration and the use of extended-release formulation as tools for minimizing side effects but were uncertain about the effectiveness of these strategies.ConclusionMetformin is positively viewed by patients and providers, but gastrointestinal side effects are a barrier to its use. There is some consensus on basic measures to improve its tolerability, but these measures are not consistently applied and lack evidence establishing their effectiveness. Pragmatic clinical trial research on optimal dose, formulation, and counseling for new metformin users should be considered.© 2019 Flory et al.

5 keywords...

hide…